Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389064 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
NCT00389064 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 450 participants.
The verdict
NCT00389064, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder. PLEASE NOTE: Seroquel SR and Seroquel extended release(XR) refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Interventions
- DRUG Placebo
- DRUG Quetiapine XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389064
The ClinicalTrials.gov registry entry for NCT00389064 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00389064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00389064 about?
NCT00389064 is a clinical study titled "Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder". The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder. PLEASE NOTE: Seroquel SR and Seroquel extended release(XR) refer to the s...
What is the current status of trial NCT00389064?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2006-09. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00389064?
The interventions under investigation include: Placebo (DRUG), Quetiapine XR (DRUG).
Who is sponsoring clinical trial NCT00389064?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.